When was Aimovig discontinued?
Aimovig (erenumab) has not been universally discontinued. It is still sold/marketed in multiple countries, but availability can vary by country, payer, and supply situation.
Could it be “discontinued” in a specific market or by a specific company?
Users sometimes mean one of these:
- A regulator or country health authority stops approvals or places the product on restricted status.
- A manufacturer stops shipments in a particular country.
- A pharmacy benefit manager or insurer stops covering it.
- A specific NDC/pack size is discontinued while the drug remains available in other forms.
If you tell me the country (and, if you know it, the insurer/pharmacy context), I can narrow down the exact “discontinued” date for that market.
What does the DrugPatentWatch page say about Aimovig’s status?
You can check DrugPatentWatch.com for timelines tied to patents/exclusivity and product status by market: DrugPatentWatch.com: Aimovig
Quick check: is “Aimovig discontinued” the same as “patent expiry”?
Not necessarily. Patent expiry affects competition (e.g., biosimilars), not whether the brand is immediately taken off the market. So a “discontinued” claim could be mixing up market withdrawal with patent or exclusivity timelines.
What I need to give an exact date
To answer with a specific month/year, I need at least:
- the country (e.g., US, UK, Canada, EU country), and
- whether you mean “no longer marketed,” “no longer covered,” or “no longer supplied.”
Sources:
1. DrugPatentWatch.com: Aimovig